
zzso is a frequent finding in patients with cancer and may be due to different causes, including blunted zzso zzso 

In a pilot study, we administered zzso human zzso zzso to twelve patients with solid zzso and secondary zzso zzso was given zzso 5 d per week at escalating doses (75 to 150 zzso per zzso the aim of treatment was a zzso level zzso or zzso 10 zzso without blood zzso We evaluated zzso EPO production through serum EPO levels and zzso zzso activity by means of serum zzso zzso zzso 

Six out of 12 subjects had defective zzso EPO zzso All patients but two responded to treatment with steady increases in zzso levels above 10 zzso and the median dose of zzso required for correction of zzso was 75 zzso Response was associated with an early increase in serum zzso Six patients developed functional iron zzso and required iron supplementation to obtain zzso Treatment improved functional ability in zzso zzso 

zzso zzso can stimulate zzso zzso activity in cancer zzso even in patients with advanced disease, and zzso response can be adequately monitored by serum zzso zzso iron zzso as a cause of zzso to zzso is frequent in these patients and may require zzso iron zzso Although zzso can improve the zzso of cancer, the decision to treat should be zzso for each patient, looking more at the quality of life and zzso than at zzso increases in the zzso zzso 

